Author:
Li Ning,Xu Jianzhong,Yan Xi,Liu Qing,Zhang Mingqi
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Sung, H., Ferlay, J., & Siegel, R. L., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209–249.
2. Yin, L., Duan, J. J., & Bian, X. W., et al. (2020). Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research, 22(1), 61.
3. Ferlay, J., Soerjomataram, I., & Dikshit, R., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359–E386.
4. Lin, N. U., Claus, E., & Sohl, J., et al. (2008). Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer, 113(10), 2638–2645.
5. Bianchini, G., Balko, J. M., & Mayer, I. A., et al. (2016). Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nature Reviews Clinical Oncology, 13(11), 674–690.